Gabapentin (GBP) is a first-line therapy for neuropathic pain, but its mechanisms and sites of action remain uncertain. We investigated GBP-induced modulation of neuropathic pain following spinal nerve ligation (SNL) in rats. Intravenous or intrathecal GBP reversed evoked mechanical hypersensitivity and produced conditioned place preference (CPP) and dopamine (DA) release in the nucleus accumbens (NAc) selectively in SNL rats. Spinal GBP also significantly inhibited dorsal horn wide-dynamic-range neuronal responses to a range of evoked stimuli in SNL rats. By contrast, GBP microinjected bilaterally into the rostral anterior cingulate cortex (rACC), produced CPP, and elicited NAc DA release selectively in SNL rats but did not reverse tactile allodynia and had marginal effects on wide-dynamic-range neuronal activity. Moreover, blockade of endogenous opioid signaling in the rACC prevented intravenous GBP-induced CPP and NAc DA release but failed to block its inhibition of tactile allodynia. Gabapentin, therefore, can potentially act to produce its pain relieving effects by (a) inhibition of injury-induced spinal neuronal excitability, evoked hypersensitivity, and ongoing pain and (b) selective supraspinal modulation of affective qualities of pain, without alteration of reflexive behaviors. Consistent with previous findings of pain relief from nonopioid analgesics, GBP requires engagement of rACC endogenous opioid circuits and downstream activation of mesolimbic reward circuits reflected in learned pain-motivated behaviors. These findings support the partial separation of sensory and affective dimensions of pain in this experimental model and suggest that modulation of affective-motivational qualities of pain may be the preferential mechanism of GBP's analgesic effects in patients.
Introduction
Effective treatments for chronic neuropathic pain remain an important unmet medical need. Currently, available medications achieve clinically significant pain relief in only about 40% to 60% of patients. 15 Neuropathic pain can result from injury or disease of the nervous system 7 and is variably characterized by allodynia and hyperalgesia (ie, enhanced response to normally innocuous or noxious stimuli, respectively). Many patients also suffer from ongoing pain that is independent of external evoked stimuli. 2, 54 Ongoing pain diminishes patients' quality of life and causes them to seek medical attention for pain relief. 2, 54 Gabapentinoids, including pregabalin and gabapentin (GBP), are first-line treatments for neuropathic pain, but their mechanisms and sites of action remain uncertain. 41, 45, 55, 66 Gabapentin demonstrates higher efficacy for neuropathic, than postoperative, pain with numbers needed to treat to benefit of 5.8 and 11, respectively. 41, 56 In patients with neuropathic pain, GBP alleviated ongoing pain, but had no effect on pain thresholds to mechanical and heat stimuli. 1 In preclinical neuropathic pain models, gabapentinoids effectively reversed tactile and thermal allodynia, but produced negligible effects on acute nociception. 29 Studies in a 2 d-1 knockout and mutant mice demonstrated that the antiallodynic effects of gabapentinoids required this subunit of voltage-gated calcium channels. 19, 48 Preclinical findings suggest that gabapentinoids may produce antiallodynic effects in the spinal cord by inhibiting neurotransmitter release. 18, 40 A clinical trial with patients with chronic pain, however, found no analgesic effects of intrathecal (i.th.) GBP infusion, 53 suggesting that supraspinal sites may be necessary. Indeed, neuroimaging in healthy subjects with experimental capsaicininduced hyperalgesia identified brain regions where GBP reduced blood-oxygen-level dependent (BOLD) functional magnetic resonance imaging (fMRI) activity in response to mechanical stimulation of the sensitized skin including the anterior cingulate, insular, and secondary somatosensory cortices, thalamus and the brainstem. 31, 64 The involvement of supraspinal sites was also demonstrated in patients with fibromyalgia, where reduction in the pain assessment following oral GBP treatment for 14 days correlated with reduced glutamate levels in the insula and decreased insular connectivity with the default mode network. 25 Pain is an unpleasant experience with both sensory and affective dimensions. Previous rodent studies have shown that the aversiveness of pain, and its relief, can be assessed independently of reflexive measures with conditioned place preference (CPP) or conditioned place aversion (CPA) testing. 32, 33, 35 Importantly, these are learning paradigms that depend on pain processing in the brain. Using this approach, i.th. clonidine, an a 2 -adrenergic receptor agonist effective in humans, produced CPP selectively in rodent experimental models of neuropathic pain (eg, spinal nerve ligation, SNL). 35 Clonidine, and other nonopioid pain-relieving treatments, also increased extracellular dopamine (DA) levels in the nucleus accumbens (NAc). 67 The reward of pain relief and activation of the mesolimbic DA pathway has been shown in multiple models of ongoing pain. 42 , 44 Here, we used CPP and NAc DA release as measures of relief of pain-related aversiveness along with evaluation of evoked hypersensitivity and spinal cord electrophysiology to investigate the effects of GBP at spinal and supraspinal sites on affective and sensory aspects of pain.
Materials and methods

Animals
Male, Sprague-Dawley rats (Harlan) weighing 250 to 350 g at the time of testing, were maintained in a climate-controlled room on a 12-hour light and dark cycle, and food and water were available ad libitum. All experiments were performed in accordance with the policies and recommendations of the International Association for the Study of Pain and the National Institutes of Health guidelines for handling and use of laboratory animals and received approval from the Institutional Animal Care and Use Committee of the University of Arizona, AZ or by Biological Services, UCL, UK. All efforts were made to minimize animal suffering and reduce the number of animals used. All behavioral experiments were performed by investigators blinded to the treatment groups.
Surgical procedures
Intracranial rostral anterior cingulate cortex cannulation
Animals were anesthetized with a ketamine (80 mg/kg; intraperitonally [i.p.]; Western Medical Supply) and xylazine (12 mg/kg; i.p.; Sigma) mixture and placed in a stereotaxic apparatus. Bilateral cannulation of the rostral anterior cingulate cortex (rACC) was performed as previously described. 32, 43 A pair of stainless steel guides (33 gauge) were implanted 1 mm above the rACC injection site (anteroposterior [AP]: bregma 12.6 mm; mediolateral [ML]: midline 6 0.6 mm; dorsoventral [DV] : skull 21.6 mm 51 ). Guide cannulas were cemented in place and secured to the skull by small stainless steel machine screws. Stainless steel dummy cannulas extending to the tip of the guide cannulas were inserted to keep the guide free of debris until drug delivery. Rats then received subcutaneous injection of gentamicin (1 mg/mL) and were allowed to recover for 7 to 10 days. Subsequently, the rats received SNL or sham surgeries. No signs of weight loss or distress were observed following cannulation surgeries.
Intrathecal cannulation
Animals were anesthetized with an i.p. injection of a mixture of ketamine (80 mg/kg) and xylazine (12 mg/kg) and placed in a stereotaxic apparatus. The atlanto-occipital membrane was exposed, cleared, and an incision was made in the dura mater. A length of PE-10 tubing was advanced 7.5 cm caudally to the lumbar spinal cord. The tubing was exteriorized, filled with saline, and heat sealed. The wound was closed and rats then received subcutaneous gentamicin (1 mg/mL) injection and were allowed to recover for 7 to 10 days before any subsequent SNL or sham surgeries and behavioral testing.
Spinal nerve ligation
The surgical procedure for L 5 and L 6 SNL was performed according to Kim and Chung. 34 Anesthesia was induced with 5% and maintained with 2% isofluorane in air. A 2-cm midline incision was made in the skin at the level of the hip bone, and the transverse process at L 5 was removed. The L 5 and L 6 spinal nerves were tightly ligated with 4-O silk suture. The incision was closed, and the animals received subcutaneous gentamicin (1 mg/mL) injection. Sham-operated control rats were prepared in an identical manner except that the L 5 and L 6 spinal nerves were not ligated. Rats were allowed to recover for 10 to 12 days. The behavior of the rats was monitored carefully for any visual indication of motor disorders or change in weight or general health. Rats that exhibited motor deficiency or that failed to develop tactile allodynia were excluded from further testing.
Nucleus accumbens microdialysis cannulation and dual nucleus accumbens/rostral anterior cingulate cortex cannulation
All stereotaxic surgeries were performed in rats anesthetized with a ketamine/xylazine mixture (80/120 mg/kg, i.p.), and cannulas were implanted according to the Paxinos brain atlas 51 to perform the microdialysis experiments. 67 For NAc microdialysis with intravenous or i.th. treatments, a single guide cannula (AG-8; Eicom Corp, San Diego, CA) was implanted vertically into the left NAc shell: (AP: bregma 11.7 mm; ML: midline 11.0 mm; DV: skull 26.0 mm). For microdialysis studies requiring bilateral rACC injections, 26-guage guide cannulas (Plastics One, Roanoke, VA) were implanted into the rACC at a 25˚forward facing angle (AP: bregma 14.1 mm; ML: midline 60.8; DV: 23.0 mm) together with the microdialysis NAc guide cannula (AP: bregma 11.7 mm; ML: midline 11.0 mm; DV: skull 26.0 mm). After surgery, rats received subcutaneous gentamicin (1 mg/mL) injection. All animals were housed individually and allowed a minimum of 7 days to recover.
Drug administration
All injections were delivered in a separate room to avoid any possible effects of injection-induced stress vocalizations on the CPP behaviors of the rats. Gabapentin was dissolved in distilled water. Systemic GBP was administrated by intravenous injection (50 mg/kg). Human dosing of Neurontin (300-600 mg, per os) corresponds to approximately 5 to 10 mg/kg. We used a dose 5-to 10-fold higher to account for faster rate of elimination in rats. 61, 65 This dose is based on previous studies that used i.p. or subcutaneous dosing of 100 mg/kg in rats. 17, 23, 24, 38 At this dose, GBP did not produce sedation. 23 Moreover, i.p. administration of GBP at doses up to 300 mg/kg in rats did not affect heart rate and blood pressure. 68 For spinal drug administration, 5 mL of saline or GBP (200 mg/5 mL) 20, 68 was injected slowly through the i.th. catheter, followed by a 1 mL air bubble and 9 mL saline flush. Clinical studies with continuous i.th. administration of GBP in patients with intractable noncancer pain used doses ranging from 1 to 30 mg/d. 53 Based simply on body weight, this would translate to 5 to 150 mg in rats. Microinjections into the rACC were performed through injectors protruding 1 mm beyond the guide cannula tip by slowly expelling 0.5 mL volume of GBP (100 mg/0.5 mL) or vehicle across a 1-minute period. This dose was implemented from the mouse study. 57 Gabapentin was purchased from Spectrum Chemical MFG (Gardena, CA). b-funaltrexamine (b-FNA) was purchased from Tocris (Ellisville, MO). Cocaine was obtained from the National Institute on Drug Abuse drug supply program.
Behavioral testing
Tactile hypersensitivity
The withdrawal threshold of the hind paw was measured in response to probing of the plantar surface with a series of calibrated von Frey filaments (Stoelting, Wood Dale, IL) in logarithmically spaced increments ranging from 0.41 to 15 g (4-150 N). Each filament was applied perpendicularly to the plantar surface of the left hind paw of rats kept in suspended wire-mesh cages. Withdrawal threshold was determined by sequentially increasing and decreasing the stimulus strength ("up and down" method), analyzed using a Dixon nonparametric test, and expressed as the mean withdrawal threshold. 14 
Thermal hypersensitivity
The withdrawal latency of the hind paw to an infrared radiant heat source was performed as previously described. 8 Baseline latencies were established at 17 to 25 seconds to allow a sufficient window for the detection of possible hyperalgesia. A maximal cutoff of 33 seconds was used to prevent tissue damage.
Conditioned place preference
The single trial CPP protocol was performed as previously described. 52 On preconditioning day (day 1), 13 days after either SNL or sham surgery, rats were placed into the CPP boxes with access to all chambers, and time spent in each chamber over 15 minutes was determined by an automated process. To assure no chamber preference bias before conditioning, animals spending more than 80% (720 seconds) or less than 20% (180 seconds) of the total time in a chamber were eliminated from further testing. Chamber pairings were counterbalanced between the control and drug chambers. The following day (day 2), all rats received vehicle (saline) injections either i.v. (1 mL/kg), i.th. (5 mL), or by microinjection into the rACC (0.5 mL/side; bilateral) and were immediately placed into one randomly-assigned conditioning chamber for 30 minutes without access to the other chamber. Four hours later in the afternoon, rats received the corresponding GBP treatment either i.v. (50 mg/kg, 1 mL/kg), i.th. (200 mg/5 mL), or into the rACC (100 mg/0.5 mL/side; bilateral) paired with the opposite chamber for 30 minutes. On test day (day 3), 20 hours following the afternoon pairing, rats were placed in the CPP box with access to all chambers again, and their behavior was recorded for 15 minutes for analysis of chamber preference. The CPP test is a learning paradigm where kinetics of drug administration can influence the outcome of single trial conditioning. We used i.v. GBP to promote rapid effects that allow direct pairing of GBP treatment with the CPP chamber, although this drug is given orally in humans. 41 In experiments involving blockade of opioid signaling in the rACC, after the baseline testing on day 1, the rats received bilateral injections of either vehicle (saline, 1 mL/side) or a selective irreversible m-opioid receptor antagonist b-FNA (3 mg/1 mL/side) into the rACC and then underwent conditioning and testing on days 2 and 3 as described. A total of 146 rats were used for all CPP experiments; 59 animals were excluded from the studies because of either (1) lack of development of chronic pain, (2) paralysis following i.th catheter, (3) CPP chamber bias during baseline, or (4) post hoc due to incorrect cannula placement.
In vivo microdialysis and HPLC quantification of dopamine
Microdialysis was performed in awake, freely moving animals. 67 The microdialysis probe (AI-8-2; EICOM, San Diego, CA) was inserted into the NAc with 2-mm semipermeable membrane (MW cutoff: 20 kDa) projecting beyond the guide cannula and perfused at 1.25 mL/minute with artificial cerebrospinal fluid (147.0 mM NaCl, 2.8 mM KCl, 1.2 mM MgCl 2 , and 1.2 mM CaCl 2 ). After a 90-minute washout period, a 90-minute baseline fraction was collected into prechilled (4˚C) amber Eppendorf tubes containing 1.0 mL 403 antioxidant solution (6.0 mM L-cysteine, 2.0 mM oxalic acid, and 1.3% wt/vol glacial acetic acid). 28 Rats were then treated with the appropriate drug, and a 90-minute experimental fraction was collected. In experiments involving b-FNA pretreatment, b-FNA was administrated into the rACC 1 day before the microdialysis experiment. After testing, all rats were injected with cocaine (20 mg/kg, i.p.), and dialysates were collected for an additional 60 minutes.
Fractions were analyzed using Agilent 1100 HPLC system (Agilent, Santa Clara, CA) with a 5020 guard cell, MD-150 column, and Coulochem III 5014B electrochemical detector (Thermo Fisher Scientific, Waltham, MA) at ambient temperature. The guard cell was set at 350 mV, Electrode1 at 2150 mV and Electrode2 at 250 mV. A standard curve was produced from 6 serial dilutions of DA (1.25-40 pg) in 20 mL artificial cerebrospinal fluid plus antioxidant cocktail. The limit of detection (LOD) and limit of quantification (LOQ) were calculated according to the following formulas: LOD 5 3.3 (SDr/S); LOQ 5 10 (SDr/S), where the SD of the response SDr (SD of y-intercepts of regression lines) and the slope of the standard curve S were determined from the measurements of 10 independent standard curves. The LOD and LOQ for DA were determined to be 0.286 and 0.868 pg on column, respectively. The linearity of DA peaks was also validated. The integration of the DA peaks from HPLC chromatograms was performed by an experimenter blinded to the treatment groups. Dopamine concentrations in the microdialysate samples were expressed as picograms per microliter. The percent change from the corresponding baseline level was calculated to normalize the variations of individual rats and to allow for multiple comparisons. Rats that had basal DA levels below the LOQ in the dialysates, or that failed to demonstrate an increase of .100% over baseline levels after cocaine administration, suggesting insufficient permeation through the microdialysis membrane, were excluded from data analysis post hoc. Ninety-six rats were used in total for the microdialysis experiments; 28 animals were excluded from the studies because of (1) the lack of allodynia in SNL rats, (2) paralysis following i.th catheterization, or (3) incorrect permeation or location of the microdialysis probe.
Electrophysiology
In vivo electrophysiology experiments were conducted on postoperative days 14 to 18 (sham and SNL-operated animals) or weight-and age-matched naive rats as previously described. 59 Animals were anesthetized and maintained for the duration of the experiment with isoflurane (1.5%) delivered in a gaseous mixture of N 2 O (66%) and O 2 (33%). Animals were secured to a stereotaxic frame. A laminectomy was performed to expose the L4-5 segments of the spinal cord. Extracellular recordings were made from deep dorsal horn neurons (lamina V-VI) using 2 MV 127 mm diameter parylene-coated tungsten electrodes (A-M systems, Sequim, WA). All the neurons recorded were wide dynamic range (WDR) and responded to natural stimuli including brush, low-and high-intensity mechanical and thermal stimuli in a graded manner with coding of increasing intensity.
The receptive fields of the neurons were on the ipsilateral hind paw within the sciatic nerve territory, typically 2 toes extending into the plantar area. A train of 16 transcutaneous electrical stimuli (2 milliseconds width and 0.5 Hz), delivered through stimulating needles inserted into the center of the peripheral receptive field, was applied at 3 times the threshold current for C-fiber activation of the dorsal horn WDR cell (typically around 3 mA). A poststimulus histogram was constructed, and responses evoked by Ab-(0-20 milliseconds), Ad-(20-90 milliseconds), and C-fibers (90-350 milliseconds) were separated and quantified on the basis of latency. Neuronal responses occurring after the C-fiber latency band were quantified as postdischarge (350-800 milliseconds). Activity-dependent hyperexcitability was measured as "wind-up," calculated as the difference between the total number of action potentials at C-fiber latency produced by the train of 16 electrical stimuli, and "input," which represented the postsynaptic C-fiberevoked dorsal horn neuronal response following the first of the 16 electrical stimuli in the electrical train.
The peripheral receptive field was stimulated using mechanical stimuli (brush and von Frey filaments 2, 8, 26, and 60 g) and thermal stimuli (42, 45 , and 48˚C applied with a constant water jet). All natural stimuli were applied for 10 seconds each. Data were captured and analyzed by a CED 1401 interface coupled to a Pentium computer with Spike 2 software (Cambridge Electronic Design; peri-post stimulus time histogram and rate functions).
Three baseline responses to peripheral stimuli as detailed above were characterized for each neuron before pharmacological assessment (a drug study was conducted on 1 neuron per animal only) following 3 consecutive stable control trials (10% variation for C-fiber evoked, ,20% variation for all other parameters). Neuron values were averaged to give the predrug control values. Following collection of baseline control data, GBP (BIONET research, Cornwall, UK, 10 mg/0.5 mL, dissolved in saline) was microinjected into the rACC. For spinal application, 50 mL of GBP (200 mg/50 mL) was applied slowly to the exposed spinal cord well. Each individual drug dose effect was followed for up to 60 minutes with tests performed at 10, 30, and 60 minutes. For the postdrug effects, maximal changes from predrug baseline values are plotted. Ten rats were used for electrophysiological experiments (5 rats per experiment); no animals were excluded from the studies.
Verification of rostral anterior cingulate cortex cannula placements
Following the experiments, rats were euthanized, and 0.5 mL India ink was injected into the rACC cannulas in the same manner as drug delivery. Brains were removed and postfixed in 10% formalin for a minimum of 4 hours. Brains were frozen and sliced at 30 mm, and the location of the ink recorded. Animals with incorrectly placed cannulas were excluded from the data analysis.
Statistical analysis
For analysis of evoked pain behaviors, 2-way analysis of variance (ANOVA) followed by post hoc Tukey multiple comparison test was performed. For CPP experiments, the difference score, obtained by taking the difference between the preconditioning (baseline) and postconditioning (test) time spent in the paired chamber, was examined by Student paired t test (Excel, Microsoft office). For microdialysis experiments, NAc DA levels are expressed as percent of their corresponding baseline levels for individual rats. An unpaired t test (2-tailed) was used to compare the changes of DA level in NAc shell after different treatments. All evaluations were obtained using GraphPad Prism 5 software (San Diego, CA). For electrophysiological experiments, statistical analyses were performed using SPSSV22 (IBM, Armonk, NY). Statistical differences in fiber threshold, electrical parameters, and neuronal responses to dynamic brush stimulation were determined using a paired Student t test. Differences in mechanical and thermal coding were determined using a 2-way repeated-measures ANOVA followed by Bonferroni correction for multiple paired comparisons. Sphericity was tested with Mauchly test. All data represent mean 6 SEM. Significance was set at P , 0.05. Asterisks denote statistically significant differences (*P , 0.05).
Results
Intravenous gabapentin reduces both evoked and ongoing pain in spinal nerve ligation rats promoting pain relief-motivated behavior
The analgesic effects of intravenously administered GBP on ongoing neuropathic pain were investigated in rats following SNL. This model of nerve injury-induced pain is characterized by mechanical and thermal hypersensitivity as well as by ongoing pain that can last for at least 60 days. 63 Mechanical allodynia observed in SNL rats 14 to 21 days after the surgery was reversed by i.v. GBP (50 mg/kg) in a time-dependent manner (sham: n 5 7; SNL: n 5 9 ; Fig. 1A) ; the peak effect was seen 20 minutes after administration. In the CPP test, this dose of GBP also produced significant preference for the chamber paired with the drug, revealing GBP's efficacy in relieving ongoing neuropathic pain (difference score 5 141 6 50 seconds; n 5 17; P 5 0.01; Fig.  1B) . Importantly, sham-operated rats showed no preference for the drug-paired chamber (difference score 5 38 6 45 seconds; n 5 10; Fig. 1B) , verifying that GBP is not rewarding in a normal state, and that its rewarding quality in SNL rats is likely due to relief of ongoing aversiveness associated with pain. This interpretation was supported by the outcomes of NAc DA release measurements using in vivo microdialysis in freely moving rats. Following i.v. GBP administration, only SNL rats demonstrated increased DA levels in the shell region of the NAc (70 6 13% increase in SNL (n 5 12) vs 6 6 10% in sham (n 5 11) rats; F (21) 5 1.735; P 5 0.0045; Fig. 1C). 3.2. The rewarding and motivational effects of pain relief following intravenous gabapentin are dependent on endogenous opioid signaling in the rostral anterior cingulate cortex Our previous studies suggest that endogenous opioid signaling in the rACC is required for reward from pain relief following opioid and nonopioid treatment. 43 To determine whether GBP also relies on this mechanism for its pain relieving effects, we injected an irreversible m-opioid receptor antagonist b-FNA (3 mg/1 mL) or vehicle (saline, 1 mL) into the rACC, and 24 hours later measured GBP-induced CPP and NAc DA release. Microinjections of saline or b-FNA into the rACC did not have any effects on the antiallodynic efficacy of i.v. GBP in SNL rats (saline: n 5 4; b-FNA: n 5 6; Fig. 2A) . However, SNL rats that received saline into the rACC showed robust CPP to i.v. GBP paired chamber (difference score 5 177 6 61 seconds; n 5 7; P , 0.01, Fig. 2B ), whereas no significant CPP was observed in SNL rats pretreated Fig. 2C ). These data suggest that endogenous opioid signaling in the rACC is required for rewarding actions of i.v. GBP-mediated relief, but is not necessary for the antiallodynic effects on evoked tactile responses. Gabapentin might therefore exert different analgesic effects by engaging spinal or supraspinal sites. For this reason, we further investigated whether gabapentin can act directly in the rACC to relieve aversiveness or whether these effects are indirect through binding of gabapentin to its targets in the spinal cord.
Intrathecal actions of gabapentin are sufficient to reduce evoked and ongoing pain in spinal nerve ligation rats
Spinal nerve ligation and sham-operated rats received a spinal injection of GBP (200 mg) through an i.th. catheter, and paw withdrawal thresholds to tactile stimuli or paw withdrawal latencies to noxious radiant heat were measured at 20, 40, 60, 90, and 120 minutes after the injection. Rats with SNL showed a significant (P , 0.05) decrease in paw withdrawal thresholds and paw withdrawal latencies to tactile and thermal stimuli, respectively (Figs. 3A and B). Intrathecal GBP produced a time-dependent reversal of SNL-induced tactile allodynia observed between 20 and 120 minutes after GBP administration, whereas i.th. saline had no effect (saline: n 5 9; GBP; n 5 10; Fig. 3A ). Spinal nerve ligation-induced thermal hyperalgesia was also transiently reduced by i.th. GBP but not by saline (saline; n 5 9; GBP; n 5 10; Fig. 3B ). These treatments had no effects on evoked behaviors in animals with sham surgeries (not shown).
In the CPP test, the same dose of i.th. GBP produced significant preference for the chamber paired with the treatment, indicating GBP's efficacy in relieving ongoing (spontaneous) neuropathic pain (difference score 5 194 6 51 seconds; n 5 10; P 5 0.0041; Fig. 3C ). Sham-operated rats did not show any preference for the chamber associated with GBP (difference score 5 27 6 57 seconds; n 5 12; Fig. 3C ). Microdialysis experiments in SNL rats demonstrated elevated levels of DA in the NAc following i.th. administration of GBP but not following i.th administration of saline (129 6 62% increase after GBP; n 5 8 vs 18 6 17% following saline; n 5 7; p 5 ns; Fig. 3D ). Together, these data support a notion that GBP can act directly in the spinal cord to inhibit evoked nociceptive signaling and indirectly through supraspinal sites including opioid circuits in the rACC to relieve ongoing pain and motivate behaviors.
Intrathecally administered gabapentin reduces evoked dorsal horn neuronal responses in spinal nerve ligation rats
We performed in vivo electrophysiology in spinal nerve ligated rats (n 5 5) and demonstrated that GBP applied directly to the spinal cord significantly inhibited WDR neuronal responses to noxious mechanical (P , 0.05 for 26 and 60 g von Frey forces; 2-way repeated measures ANOVA [RM-ANOVA]; P 5 0.022; F (1,4) 5 13.29; Fig. 3E ) and noxious thermal (P , 0.05 for 48˚C only; 2-way RM-ANOVA; P 5 0.172; F (1,4) 5 2.754; Fig. 3F ) stimuli. Furthermore, compared with predrug baselines, Ad-and C-fiber responses, input and brush responses were also significantly reduced (P 5 0.005; 0.034; 0.036; and 0.000 respectively; paired sample t Test; Fig. 3G ). The maximal change from baseline was observed either at 10 or 30 minutes depending on the animal.
Administration of gabapentin into the rostral anterior cingulate cortex is sufficient to elicit CPP and NAc dopamine release in SNL rats without modulating evoked pain responses
To determine whether GBP can directly act in the rACC to alleviate aversiveness associated with ongoing pain, we injected vehicle (saline; 0.5 mL/site) or GBP (100 mg/0.5 mL/site) into the rACC of SNL or sham rats. In injured rats, neither saline nor GBP in the rACC had any effect on nerve ligation-induced tactile allodynia (n 5 5; Fig. 4A ). However, in SNL rats, microinjection of GBP into the rACC produced CPP, indicated by significant difference score (189 6 56 seconds; n 5 8; P 5 0.0116; Fig. 4B ). Gabapentin did not produce CPP in sham-operated rats (15 6 48 seconds; n 5 8; P 5 0.7661; Fig. 4B) . Consistent with the CPP data, rACC microinjection of GBP significantly increased DA levels in the NAc in SNL rats (103 6 43% increase following GBP [n 5 5] vs 8 6 12% following saline [n 5 8]; F (11) 5 7.464; P 5 0.026; Fig. 4C ). Therefore, GBP may have additional supraspinal sites of action including the rACC where it may directly modulate aversive aspects of pain independently of its spinal effects.
3.6. Administration of gabapentin in the rostral anterior cingulate cortex has no effect on evoked dorsal horn neuronal responses to natural stimuli and minimal effects on electrically evoked dorsal horn neuronal responses in spinal nerve ligation rats
To investigate if GBP action in the rACC could result in the engagement of descending pain modulatory pathways to inhibit neuronal activity at the spinal cord level, we measured electrophysiological responses of WDR neurons following administration of GBP into the rACC of SNL rats (n 5 5). Compared with baseline, GBP had no significant effect on evoked WDR neuronal responses to mechanical or thermal stimuli (P . 0.05 for all natural stimuli; 2-way RM-ANOVA; P 5 0.052, F (1,4) 5 6.634 and P 5 0.058, F (1,4) 5 6.27, respectively) (Figs. 4D and E). We did, however, observe that rACC GBP had a significantly inhibitory effect on a subset of electrically evoked WDR neuronal responses at 10 or 30 minutes time point (C-fiber activity and postdischarge, P 5 0.043 and 0.032, respectively; paired sample t test) (Fig. 4F) . Saline microinjection into the rACC had no effect on WDR neuronal-evoked responses to natural or electrical stimuli (P . 0.05 for all stimuli; 2-way RM-ANOVA; P 5 0.565, F (1,4) 5 0.393) (data not shown).
Discussion
Gabapentin and pregabalin were designed as analogs of g-aminobutyric acid (GABA), but they do not bind to either ionotropic or metabotropic GABA receptors. Instead, these drugs exhibit high affinity for the a 2 d-subunits of voltage-gated calcium channels. 21 The use of a 2 d-1 knockout and mutant mice established the requirement of this subunit for the analgesic effects of gabapentinoid drugs presumably by modulation of transmitter release in the spinal cord. 19, 48 It is, therefore, surprising that gabapentinoids have minimal effects on nociceptive transmission, and promote analgesia only in states with central sensitization, as demonstrated in an experimental setting of capsaicin-induced secondary hyperalgesia in humans 31 and in rodent models of trauma-or chemotherapy-induced neuropathic pain. 1, 5, 29, 37, 46 Animal studies of neuropathic pain have repeatedly demonstrated spinal sites of action for GBP in the modulation of evoked hypersensitivity. 10, 11, 30, 47 Consistent with this possibility, neuroimaging studies with capsaicin-induced sensitization in humans showed reduced BOLD signaling in brain regions processing nociceptive input from the spinal cord, including the insula, the secondary somatosensory cortex (SII), and the brainstem, potentially reflecting GBP effects on spinal dorsal horn neurons. 31, 64 Alternatively, these results might be explained by direct GBP effects in the brain. Contributing to the uncertainty of how GBP may produce its effects, a recent clinical trial investigated the effects of continuous i.th. GBP infusion through an implanted drug delivery system in chronic patients with pain and surprisingly found no reduction in numerical pain rating scale or physical function, quality of life, or emotional functioning. 53 Common sideeffects of orally administered GBP include sedation, dizziness, and ataxia that are observed at doses used clinically for the treatment of neuropathic pain, 64 suggesting that GBP produces at least some of its effects in the brain and that supraspinal activity could contribute to its analgesic efficacy. Our findings demonstrate that GBP has direct spinal actions on dorsal horn neurons in nerve injured rats likely accounting for antiallodynic actions observed. However, although i.th. delivery is sufficient to alleviate aversiveness of ongoing nerve injury-induced pain, this requires activation of endogenous opioid signaling in the rACC. In addition, rACC GBP is sufficient to relieve pain aversiveness with minimal effects on spinal neuronal responses to evoked stimuli and without reversing tactile allodynia. Collectively, these findings likely reflect direct actions of GBP in the rACC to modulate affective qualities of pain and spinal effects to modulate evoked hypersensitivity.
Effects of gabapentin in the spinal cord
Substantial evidence from animal studies suggests that after nerve injury, there is an upregulation of a 2 d-1 in dorsal root In SNL rats, rACC administration of GBP had no effect on the responses of WDR neurons to noxious mechanical stimulation (n 5 5). (E) Gabapentin injections into the rACC had no effect on the responses of WDR neurons to heat stimulation (n 5 5). (F) Significant inhibitory effects of rACC GBP were observed for C-fiber and post-discharge responses (n 5 5; *P , 0.05 compared to predrug baseline). Data are mean 6 SEMs. CPP, conditioned place preference; DA, dopamine; GBP, gabapentin; NAc, nucleus accumbens; rACC, rostral anterior cingulate cortex; SNL, spinal nerve ligation; WDR, wide dynamic range. ganglion neurons 13, 39, 62 and in the spinal cord 3, 6 that may contribute to neuronal hyperexcitability and spinal sensitization. Gabapentin binding to the a 2 d-1 subunit on presynaptic terminals of primary nociceptors in the dorsal horn of the spinal cord has been considered the key mechanism of antiallodynic and antihyperalgesic effects (see Ref. 49 for review). However, studies in cultured dorsal root ganglion neurons demonstrate that GBP requires more than 17 to 20 hours to inhibit calcium current through binding to the a 2 d-1 subunit where neurotransmitter release may be influenced. 26 By contrast, in vivo behavioral and electrophysiological studies have shown that i.th. GBP elicits effects within minutes. 10, 11, 30 Therefore, the molecular mechanism of spinal effects remains unclear.
Consistent with these previous observations, our data demonstrate that in anesthetized SNL rats, spinal application of GBP inhibits evoked neuronal discharge of spinal WDR neurons with effects observed typically within 10 minutes following application, and a maximal inhibition typically observed by 30 minutes. Spinal GBP significantly suppressed the WDR neuronal activity evoked by noxious mechanical and thermal stimuli, as well as by electrical stimulation of Ad-and C-fibers, input and brush. Likewise, intrathecal GBP time dependently reversed both mechanical and thermal hypersensitivity in SNL rats, without producing changes in response thresholds in sham-operated rats, supporting direct inhibition of WDR neurons in the antihyperalgesic and antiallodynic effects. Intrathecal GBP also elicited CPP and DA release in the NAc specifically in SNL rats, reflecting relief of aversiveness associated with ongoing pain. These antiaversive effects of spinally administered GBP are ultimately mediated through supraspinal circuits, however, as both CPP and NAc DA release were abolished by blockade of opioid signaling in the rACC.
Supraspinal effects of gabapentin
The a 2 d-1 is also expressed in supraspinal sites including the areas involved with pain processing, such as the cingulate cortex, amygdala, and the brainstem 12, 58 (Allen brain atlas). Gabapentin is an anticonvulsant and at analgesic doses readily crosses the blood-brain barrier in both humans and rodents. 4, 36 Effects of systemic GBP on BOLD activity have been demonstrated using pharmacological MRI (phMRI) in naive and SNL rats. 22, 27 Importantly, neuroimaging studies in healthy human subjects have demonstrated reduced mechanical stimulus-mediated BOLD functional magnetic resonance imaging activity during the oral GBP session in the insular cortex, the ACC, and the SII. 31 The ACC, along with the thalamus and the brainstem, were also regions with increased activity during capsaicin-induced central sensitization. In a mouse model of neuropathic pain, intracerebroventricular GBP or pregabalin increased spinal norepinephrine levels and reduced mechanical and thermal hypersensitivity, suggesting activation of descending pain inhibitory pathways from locus coeruleus. 57 Whether GBP can alleviate affective features of ongoing pain by directly modulating the activity in these central circuits has not been determined.
Previously, we have reported that endogenous opioid activity within the rACC is required for CPP and NAc DA release following nonopioid, nonaddictive treatments, such as peripheral nerve block or spinal clonidine in rats with incisional or neuropathic pain, respectively. 43 Consistent with these findings, blockade of m-opioid receptors in the rACC with b-FNA blocks i.v. GBPinduced CPP and NAc DA release in SNL rats, demonstrating that opioid signaling in the rACC may represent a general mechanism necessary for relief of pain aversiveness. Also in agreement with our previous findings, 43 pretreatment of rACC with b-FNA had no influence on the antiallodynic actions of i.v. GBP, implying that the antiallodynic effects are likely mediated at the spinal level and are partially separated from the affective aspects of pain. Direct microinjection of GBP (100 mg) into the rACC was sufficient to produce CPP selectively in rats with neuropathic pain. Intra-rACC GBP also resulted in increased DA release in the NAc selectively in SNL but not sham rats, indicating that GBP can act in this brain region to relieve pain-induced aversiveness and facilitate pain relief-motivated behavior. By contrast, rACC GBP had no effect on nerve injury-induced mechanical allodynia. In spinal cord electrophysiological studies, rACC GBP had no effect on noxious mechanical and thermal responses of WDR neurons. However, rACC GBP produced a small, but significant, inhibitory effect on electrically evoked excitability of spinal neuronal responses for C-fiber activity and postdischarge. This indicates that rACC GBP might inhibit afferent nociception at the spinal cord level by engaging the descending pain modulatory pathways, although in our study, this effect was not sufficient to attenuate mechanical allodynia. Imaging studies in humans demonstrate that emotions and placebo analgesia can activate circuitry from the anterior cingulate cortex to the periaqueductal gray area in the brainstem to modulate unpleasantness of pain. 9, 16, 60 The same circuitry may therefore be involved in the observed effects on WDR neurons. It is noteworthy that GBP (100 mg) injected intracerebroventricularly in mice with neuropathic pain was able to engage the descending pain inhibitory pathways directly from the brainstem. 57 Likewise, in subjects with capsaicin-induced hyperalgesia, oral GBP attenuated stimulusevoked neural activity in the brainstem descending pain modulatory regions. 31, 64 Systemic pregabalin in SNL rats attenuates mechanical evoked activity but not ongoing activity of thalamic neurons, part of the pathways that comprise the sensory components of pain. 50 Thus, it is possible that although these agents can attenuate the ongoing aversive state produced by neuropathy as we show in the present study, they may not alter the ongoing nociceptive input.
It is important to point out that pharmacokinetics of GBP in humans and rodents is different, 61 which may explain higher systemic and i.th. doses used in this and other rodent studies. 17, 20, 23, 24, 38, 68 For intra-rACC injections, we used 10 and 100 mg in anesthetized and awake rats, respectively. Following oral dosing of 200 mg/kg in rats, a PK/PD study observed maximum concentration of GBP in the brain's extracellular fluid at approximately 10 mg/mL. 61 Thus, central nervous system tissue concentrations of GBP following intra-rACC injections are likely higher than those achieved following systemic dosing in rats. Concentrations that are achieved clinically in specific brain regions relevant to the actions of GBP remain unknown.
In conclusion, this study provides evidence that GBP can act directly in the spinal cord to suppress nociceptive responses of spinal cord neurons and attenuate nerve injury-induced hypersensitivity. As the affective qualities of pain are closely linked to intensity of nociceptive inputs, spinal actions of GBP were also shown to be sufficient to reduce pain aversiveness. Ultimately, however, pain relief-motivated behavior, but not evoked hypersensitivity, requires engagement of endogenous supraspinal circuits including opioid signaling in the rACC and DA signaling in the NAc. Gabapentin may also act directly in the rACC to modulate pain without significantly changing evoked hypersensitivity. Whether rACC GBP can modulate descending pain pathways to inhibit nociceptive traffic at the spinal cord requires further study, but preclinical investigations have shown that GBP can act in the brainstem to engage descending pain modulatory pathways. Thus, the clinical efficacy of GBP could reflect the outcome of congruent effects at spinal and supraspinal sites that modulate different aspects of pain. Reduction of pain is ultimately the main goal of pain therapy and it is likely that in patients with neuropathic pain, supraspinal actions preferentially contribute to GBP's analgesic effects.
